VOSE vs. MOSE in EUS-FNB for Pancreatic Masses
Comparison of Specimen Quality Using Visual On-Site Evaluation Versus Macroscopic On-Site Evaluation in Endoscopic Ultrasound-Guided Fine Needle Biopsy of Solid Pancreatic Masses: A Prospective, Multicenter, Randomized Controlled, Non-Inferiority Trial
The primary endpoint of this study was to evaluate whether the histopathological diagnostic accuracy of VOSE EUS-FNB using 22-gauge (22G) Franseen or 22G Trident (Trident™) needles is non-inferior to that of MOSE EUS-FNB in pancreatic solid masses. The secondary endpoints included diagnostic sensitivity, diagnostic specificity, median number of needle passes, puncture time, and cytological diagnostic accuracy.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200025
- Ruijin hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age above 18 years, male or female.
- Presence of a solid pancreatic mass detected by CT, MRI, PET-CT, or EUS, and scheduled for EUS-FNB for diagnostic purposes.
- Provision of signed written informed consent.
Exclusion Criteria:
- Contraindications to endoscopy, such as severe cardiovascular or cerebrovascular diseases.
- Coagulation disorders (International Normalized Ratio [INR] ≥ 1.5, platelet count ≤ 50 × 10^9/L) or current use of anticoagulant or antiplatelet medications.
- Confirmed or suspected pregnancy.
- Pathological diagnosis has already been established by other methods.
- Refusal to participate in the study, current participation in another clinical trial, or participation in another clinical trial within 60 days prior to enrollment.
- Any other conditions that preclude the performance of EUS-FNB.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:診断
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:VOSE Group (Visual On-Site Evaluation)
Patients undergo EUS-FNB using 22G Franseen or 22G Trident needles. The first pass specimen is pushed onto a slide, and visible tissue cores are placed into formalin for visual grading. If no "red mixed specimen" is observed, additional passes are performed up to 3 passes. The number of passes and puncture time are recorded. |
VOSE group:During the EUS-FNB procedure, the first-pass specimen is pushed onto a slide. Visible tissue cores are placed into a formalin vial, gently shaken to dissolve blood, and visually graded with photographic recording. If the first-pass specimen is not a "red mixed specimen," additional passes are performed until a "red mixed specimen" appears or a maximum of 3 passes is reached. |
|
アクティブコンパレータ:MOSE Group (Macroscopic On-Site Evaluation)
Patients undergo EUS-FNB using 22G Franseen or 22G Trident needles. The first pass specimen is pushed onto a slide, and the macroscopic visible core (MVC) length is measured. If the MVC is < 10mm, additional passes are performed until the total MVC is ≥ 10mm or up to 3 passes. The number of passes and puncture time are recorded. |
MOSE group:During the EUS-FNB procedure, the first-pass specimen is pushed onto a slide, and the length of the macroscopic visible core (MVC) is measured. If the total MVC length is less than 10 mm, additional passes are performed until the total MVC is ≥ 10 mm or a maximum of 3 passes is reached. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Histopathological diagnostic accuracy
時間枠:Within 30 days after the EUS-FNB procedure
|
The diagnostic accuracy of histopathological tissue obtained by EUS-FNB in the VOSE group compared to the MOSE group, using the final surgical pathology or clinical/radiological follow-up as the gold standard. |
Within 30 days after the EUS-FNB procedure
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Diagnostic sensitivity
時間枠:Within 30 days after the EUS-FNB procedure
|
The diagnostic sensitivity of VOSE and MOSE groups compared to the final gold standard diagnosis. |
Within 30 days after the EUS-FNB procedure
|
|
Diagnostic specificity
時間枠:Within 30 days after the EUS-FNB procedure
|
The diagnostic specificity of VOSE and MOSE groups compared to the final gold standard diagnosis. |
Within 30 days after the EUS-FNB procedure
|
|
Median number of needle passes
時間枠:During the EUS-FNB procedure
|
The number of needle passes required to obtain adequate tissue samples (until a "red mixed specimen" or MVC ≥ 10mm is observed, up to 3 passes). |
During the EUS-FNB procedure
|
|
Puncture time
時間枠:During the EUS-FNB procedure
|
The duration of the puncture procedure (from the start of the first needle pass to the end of sampling). |
During the EUS-FNB procedure
|
|
Cytological diagnostic accuracy
時間枠:Within 30 days after the EUS-FNB procedure
|
The diagnostic accuracy of liquid-based cytology obtained from residual specimens in VOSE and MOSE groups, compared to the final gold standard diagnosis. |
Within 30 days after the EUS-FNB procedure
|
協力者と研究者
スポンサー
協力者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。